Mednax Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;'>MD</div>
MD -- USA Stock  

USD 15.41  1.37  8.16%

Mednax Enterprise Value is projected to increase significantly based on the last few years of reporting. The past year's Enterprise Value was at 4.34 Billion. The current year Free Cash Flow is expected to grow to about 355.4 M, whereas Revenue Per Employee is forecasted to decline to about 300.8 K. The underlying objective of this short story is to digest Mednax as an investment oportunity for August. We will discuss why recent Mednax price moves suggest a bounce in August.
Published over a month ago
View all stories for Mednax | View All Stories
Are Mednax (NYSE:MD) shareholders starting to hold back?
Mednax is OVERVALUED at 18.38 per share with modest projections ahead. The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Mednax has an asset utilization ratio of 77.19 percent. This indicates that the company is making $0.77 for each dollar of assets. An increasing asset utilization means that Mednax Inc is more efficient with each dollar of assets it utilizes for everyday operations.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Mednax Inc. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Predictive Modules for Mednax


How important is Mednax's Liquidity

Mednax financial leverage refers to using borrowed capital as a funding source to finance Mednax Inc ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Mednax financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Mednax's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for Mednax, but it might be worth checking our own buy vs. sell analysis

Breaking down Mednax Indicators

The latest price surge of Mednax Inc may encourage shareholders to take a closer look at the firm as it closed today at a share price of 19.58 on 644,813 in trading volume. The company executives may have good odds in positioning the firm resources to exploit market volatility in August. The stock standard deviation of daily returns for 30 days investing horizon is currently 4.84. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Mednax Inc partners.

Margin Breakdown

Operating Margin(33.18432)
EBITDA Margin(0.406421)
Gross Margin0.27
Profit Margin(0.437211)

Our perspective of the latest Mednax surge

The treynor ratio is down to 0.43 as of today. Mednax Inc shows above-average downside volatility for the selected time horizon. We advise investors to inspect Mednax Inc further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Mednax future alpha.

Our Conclusion on Mednax

Although few other entities within the medical care facilities industry are still a little expensive, even after the recent corrections, Mednax may offer a potential longer-term growth to shareholders. With a somewhat neutral outlook on your 30 days horizon, it may be better to hold off any trading activity and neither acquire new shares of Mednax nor exit your existing holdings in the Stock. It seems the expected volatility has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Mednax.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Mednax Inc. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com